Protagonist Q1 net income $3.8M on ICOTYDE approval milestone; cash $620M, rusfertide opt-out fee $200M

Protagonist Therapeutics, Inc

2026-Q1 EPS reported $0.05 revenue$56,368,000

Net income $3.8M ($0.05 diluted EPS) vs net loss $11.7M in Q1 2025; revenue $56.4M incl. $50M ICOTYDE milestone from J&J.
Cash, equivalents & marketable securities $620.3M as of March 31, 2026; expected runway through at least 2028.
ICOTYDE FDA-approved March 18 for plaque psoriasis; Protagonist eligible for up to $580M in milestones and 6-10% tiered royalties.
Exercised rusfertide opt-out April 28, triggering $200M payment due; eligible for additional $200M opt-out fee and $75M milestone plus up to $775M sales milestones and 14-29% royalties.
Rusfertide NDA granted Priority Review; PDUFA date August 2026. PN-881 Phase 1 completion by mid-2026, Phase 2 initiation expected year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Protagonist Therapeutics, Inc reported first quarter ended March 31, 2026 results: revenue License and collaboration revenue $ 56,368, net income Net income (loss) $ 3,783, EPS Diluted earnings (loss) per share $ 0.05.

Period: first quarter ended March 31, 2026
Revenue: License and collaboration revenue $ 56,368
Net income: Net income (loss) $ 3,783
EPS: Diluted earnings (loss) per share $ 0.05
Result: reported results

Exact text from the filing

to $646.0 million as of December 31, 2025. Three Months Ended March 31, 2026 2025 (in thousands, except per share amounts) (Unaudited) License and collaboration revenue $ 56,368 $ 28,321 Research and development expense $ 46,739 $ 35,893 General and administrative expense $ 13,277 $ 11,738 Income tax benefit $ 1,502 $ - Net income (loss) $ 3,783 $ (11,655

View on SEC.gov

Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-26-055629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.